You are here

Avanafil 2.00: The 2nd generation of PDE5-Is has begun


Chair: Vincenzo G. Mirone, Naples, Italy

Erectile dysfunction, a highly prevalent cause of sexual dysfunction in men, is effectively treated with a phosphodiesterase type 5 (PDE5) inhibitor in most cases. However, in a non-negligible number of cases, the patient or partner’s sexual dissatisfaction with the treatment results in discontinuation. A second-generation PDE5 inhibitor, Avanafil, was developed to address this deficiency and was recently approved in the EU. Clinical results have shown that Avanafil is a better tolerated treatment, even at the highest dosage, with rapid and sustained efficacy. Thus Avanafil provides an innovative, on-demand solution for erectile dysfunction, allowing patients to respond immediately to their partner’s wishes and obviating the need to plan sex in advance.

Industry session sponsored by The Menarini Group Sunday 13 March 2016


Sponsored by:

Search this site

E-Alert

Subscribe to our E-Alert to stay informed of all new content.

Share